| Schedule of financial information by reportable segments |
Financial information by reportable segment is as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, 2026 | | (in thousands) | | Generics and Other | | Rare Disease and Brands | | Corporate and Unallocated | | Total | | Net Revenues | | $ | 100,656 | | $ | 165,388 | | $ | — | | | $ | 266,044 | | | Cost of sales (excluding depreciation and amortization) | | 51,398 | | | 48,760 | | | — | | | 100,158 | | | Research and Development expense | | 11,186 | | | 3,561 | | | — | | | 14,747 | | | Selling, general, and administrative expense | | 1,578 | | | 60,719 | | | 29,364 | | | 91,661 | | | Depreciation and amortization | | — | | | — | | | 19,640 | | | 19,640 | | | Contingent consideration fair value adjustment | | — | | | — | | | (622) | | | (622) | | | Operating Income (Loss) | | $ | 36,494 | | | $ | 52,348 | | | $ | (48,382) | | | $ | 40,460 | | | | | | | | | | | | Unrealized gain on investment in equity securities | | $ | — | | | $ | — | | | $ | 741 | | | $ | 741 | | | Interest expense, net | | — | | | — | | | (3,636) | | | (3,636) | | | Other expense, net | | — | | | — | | | (468) | | | (468) | | | Income (Loss) Before Income Tax Expense | | $ | 36,494 | | | $ | 52,348 | | | $ | (51,745) | | | $ | 37,097 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, 2025 | | (in thousands) | | Generics and Other | | Rare Disease and Brands | | Corporate and Unallocated | | Total | | Net Revenues | | $ | 94,213 | | $ | 117,158 | | $ | — | | | $ | 211,371 | | | Cost of sales (excluding depreciation and amortization) | | 43,231 | | | 31,384 | | | — | | | 74,615 | | | Research and Development expense | | 11,414 | | | 5,121 | | | — | | | 16,535 | | | Selling, general, and administrative expense | | 1,389 | | | 51,191 | | | 29,191 | | | 81,771 | | | Depreciation and amortization | | — | | | — | | | 23,281 | | | 23,281 | | | Contingent consideration fair value adjustment | | — | | | — | | | 1,277 | | | 1,277 | | | Operating (Loss) Income | | $ | 38,179 | | $ | 29,462 | | $ | (53,749) | | $ | 13,892 | | | | | | | | | | | Unrealized gain on investment in equity securities | | $ | — | | | $ | — | | | $ | 332 | | | $ | 332 | | | Interest expense, net | | — | | | — | | | (5,438) | | | (5,438) | | | Other income, net | | — | | | — | | | 1,739 | | | 1,739 | | | Income (Loss) Before Income Tax Expense | | $ | 38,179 | | $ | 29,462 | | $ | (57,116) | | | $ | 10,525 | |
|